Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK -Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial.
DIAMOND-2 was a multicenter, randomized, open-label phase III trial comparing dirozalkib with crizotinib in adults with ALK inhibitor-naïve, ALK-positive advanced non-small-cell lung cancer.
Why it matters
The trial provides randomized phase III evidence that dirozalkib can extend progression-free survival compared with crizotinib in ALK inhibitor-naïve advanced NSCLC, with fewer severe treatment-emergent adverse events…